Diabetes mellitus

Clinics in Dermatology

Volumn 24, Issue 4, 2006, Pages 237-246

  Ahmed, Intekhab ^a   Goldstein, Barry ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMMONIUM LACTATE; AMPHOTERICIN B; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CYCLOSPORIN; DAPSONE; ERYTHROMYCIN; GLUCOCORTICOID; INSULIN; ISOTRETINOIN; METFORMIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PENICILLIN G; PENTOXIFYLLINE; PROSTAGLANDIN E1; PSORALEN; QUINOLONE DERIVATIVE; RETINOIC ACID; SORBINIL; STEROID; SULFONYLUREA DERIVATIVE; TETRACYCLINE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACANTHOSIS NIGRICANS; ARTICLE; ATROPHY; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLISTER; CAROTENODERMIA; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE COURSE; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EXTERNAL OTITIS; FIBROMA; FREEZE THAWING; GLUCOSE BLOOD LEVEL; GRANULOMA ANNULARE; HUMAN; HYPERBARIC OXYGEN; INJECTION SITE REACTION; LICHENOID ERUPTION; LIPOATROPHY; LIPOHYPERTROPHY; MEASLES LIKE RASH; MUCORMYCOSIS; NECROBIOSIS LIPOIDICA; NECROTIZING FASCIITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; PUVA; SCLEREDEMA; SKIN DISEASE; SKIN GRAFT; SKIN INFECTION; SKIN MANIFESTATION; URTICARIA;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; INSULIN; SKIN DISEASES; SKIN DISEASES, INFECTIOUS;

EID: 33745582599     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.04.009     Document Type: Article

References (100)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates on diabetes (2005). http://www.cdc.gov/diabetes/pubs/estimates.htm#prev
2. Engelgau M.M., et al. The evolving diabetes burden in the United States. Ann Intern Med 140 (2004) 945-950
3. Perez M.I., and Cohn S.R. Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 30 (1994) 519-531
4. Paron M.G., and Lambert P.W. Cutaneous manifestations of diabetes mellitus. Prim Care 27 (2000) 371-383
5. Romano G., Moretti G., et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 39 (1998) 101-106
6. Stuart C.A., Gilkison C.R., et al. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clin Pediatr 37 (1998) 73-80
7. Hermanns-Le T., Scheen A., and Pierard G.E. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol 5 (2004) 199-203
8. Veysey E., and Ratnavel R. Facial acanthosis nigricans associated with obesity. Am J Clin Dermatol 30 (2005) 437-439
9. Simha V., and Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab 88 (2003) 5433-5437
10. Apridonidze T., Essah P.A., Iuorno M.J., and Nestler J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1929-1935
11. Lobie P.E., Breipohl W., Lincoln D.T., Garcia-Aragon J., and Waters M.J. Localization of the growth hormone receptor/binding protein in skin. J Endocrinol 126 (1990) 467-471
12. Stratakis C.A., Mastorakos G., Mitsiades N.S., Mitsiades C.S., and Chrousos G.P. Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia. Pediatr Dermatol 15 (1998) 253-258
13. Musso C., Cochran E., Moran S.A., et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine 83 (2004) 209-222
14. Cruz Jr. P., and Hud Jr. J. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 98 (1992) 82S
15. Yeh J.S., Munn S.E., Plunkett T.A., et al. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol 42 2 Pt 2 (2000) 357-362
16. Stals H., Vercammen C., Peeters C., and Morren M.A. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology 189 (1994) 203-206
17. Dunaif A., Green G., and Pleps R. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 73 (1991) 590-595
18. Scheretz E.F. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Arch Dermatol 24 (1988) 1094-1096
19. Jelinek J.E. The skin and diabetes (1986), Lea & Febiger, Philadelphia
20. Ferringer T., and Miller III F. Cutaneous manifestations of diabetes mellitus. Dermatol Clin 20 (2002) 483-492
21. Lithner F. Cutaneous reactions of the extremities of diabetic to local thermal trauma. Acta Med Scand 198 (1975) 319
22. Fisher E.R., and Danowski T.S. Histologic, histochemical, and electron microscopic features of the shin spots of diabetes mellitus. Am J Clin Pathol 50 (1968) 547-554
23. Lowitt M.H., and Dover J.S. Necrobiosis lipoidica. J Am Acad Dermatol 25 (1991) 735
24. Dwyer C.M., and Dick D. Ulceration in necrobiosis lipoidica: a case report and study. Clin Exp Dermatol 18 (1993) 366
25. Petzelbauer P., et al. Necrobiosis lipoidica: treatment with systemic corticosteroids. Br J Dermatol 126 (1992) 542
26. Iwasaki T., Kohoma T., et al. Diabetic scleredema and scleroderma-like changes in a patient with maturity onset type diabetes of the young people. Dermatology 188 (1994) 228
27. Kapoor A., and Sibbitt W.L. Contracture in diabetes mellitus: the syndrome of limited joint mobility. Semin Arthritis Rheum 18 (1989) 168-180
28. Seibold J. Digital sclerosis in children with insulin-dependent diabetes mellitus. Arthritis Rheum 25 (1982) 1357-1361
29. Libecco J.F. Finger pebbles and diabetes: a case with broad involvement of dorsal fingers and hands. Acta Dermatol 137 (2001) 510-511
30. Fleischmajer R., Faludi G., and Krol S. Scleredema and diabetes mellitus. Arch Dermatol 101 (1970) 21-35
31. Silbert C., and Kleinman H.K. Studies of cultured human fibroblasts in diabetes mellitus. Changes in heparan sulphate. Diabetes 28 (1979) 61-64
32. Forst T., Kann P., et al. Association between diabetic thick skin syndrome and neurological disorders in diabetes mellitus. Acta Diabetol 31 (1994) 73-77
33. Yosipovitch G., Yosipovitch Z., Karp M., and Mukamel M. Trigger finger in young patients with insulin dependent diabetes. J Rheumatol 17 (1990) 951-952
34. Yosipovitch G., Loh K.C., and Hock O.B. Medical pearls: scleroderma-like skin changes in patients with diabetes mellitus. J Am Acad Dermatol 48 (2003) 109-111
35. Glasoe W.M., Allen M.K., Ludewig P.M., and Saltzman C.L. Dorsal mobility and first ray stiffness in patients with diabetes mellitus. Foot Ankle Int 25 (2004) 550-555
36. Samlaska C.P., et al. Generalized perforating granuloma annulare. J Am Acad Dermatol 27 (1992) 319
37. Schleicher S.M., and Milstein H.J. Resolution of disseminated granuloma annulare following isotretinoin therapy. Cutis (1985) 1
38. Setterfield J., Huilgol S., and Black M. Generalised granuloma annulare successfully treated with PUVA. Clin Exp Dermatol 24 (1999) 458
39. Suzuki K., Ito Y., Nakamura S., Ochiai J., and Aoki K. Relationship between serum carotenoids and hyperglycemia: a population-based cross-sectional study. J Epidemiol 12 (2002) 357-366
40. Lipsky B.A., Baker P.D., et al. Diabetic bullae: 12 cases of purportedly rare cutaneous disorder. Int J Dermatol 39 (2000) 196-200
41. Wahid Z., and Kanjee A. Cutaneous manifestations of diabetes mellitus. J Pak Med Assoc 48 (1998) 304-305
42. Aye M., and Masson E.A. Dermatological care of the diabetic foot. Am J Clin Dermatol 3 (2002) 463-474
43. Huntley A.C. Cutaneous manifestations of diabetes mellitus. Dermatol Clin 7 (1989) 531-546
44. Darmstadt G.L., Yokel B.K., and Horn T.D. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol 127 (1991) 1139
45. Katz R.A.:. Treatment of acanthosis nigricans with oral isotretinoin. Arch Dermatol 116 (1980) 110
46. Noz K.C., et al. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol 18 (1993) 78
47. Tidman M. Management of necrobiosis lipoidica. Clin Exp Dermatol 27 (2002) 328
48. Nguyen K., Washenik K., and Shupak J. Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol 46 2 Suppl Case Reports (2002) S34-S36
49. Stanway A., Rademaker M., and Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporin. Australas J Dermatol 45 (2004) 119-122
50. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Dermatol Venereol 2 (1992) 69
51. Blume-Peytavi U., et al. Successful outcome of cryosurgery in patients with granuloma annulare. Br J Dermatol 130 (1994) 494
52. Saied N., Schwartz R.A., and Estes S.A. Treatment of generalized annulare with dapsone. Arch Dermatol 116 (1980) 1345
53. Stables G.I., et al. Scleredema associated with paraproteinemia treated by extracorporeal photopheresis. Br J Dermatol 142 (2000) 781
54. Lee M.W., et al. Electron beam therapy in patients with scleredema. Acta Dermatol Venereol (Stockh) 80 (2000) 307
55. Grundmann-Kolloman M., et al. Cream PUVA therapy for scleredema adultorum. Br J Dermatol 142 (2000) 1058
56. Ikeda Y., et al. Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin E1. Int Med 37 (1998) 861
57. Mattheou-Vakali G., et al. Cyclosporin in scleredema. J Am Acad Dermatol 35 (1996) 990
58. Lieberman L.S., Rosenbloom A.L., Riley W.J., et al. Reduced skin thickness with pump administration of insulin. N Engl J Med 303 (1980) 940-941
59. Infante J.R., Rosenbloom A.L., Silverstein J.H., et al. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr 138 (2001) 33-37
60. Eaton P., Sibbitt W.L., and Harsh A. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients. JAMA 253 (1985) 1437-1440
61. Eaton R.P., Sibbitt W.L., Shah V.O., et al. A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes. J Diabetes Complications 12 (1998) 34-38
62. Sibbald R.G., Tooth D., et al. Skin and diabetes. Endocrinol Metab Clin North Am 25 (1996) 463-472
63. Goodfield M.J.D., and Millard L.G. The skin in diabetes mellitus. Diabetologia 31 (1988) 567-575
64. Murphy D.P., Tan J.S., et al. Infectious complications in diabetic patients. Prim Care 8 (1981) 695
65. Harrison's Principles of Internal Medicine. 14th ed (1998), McGraw-Hill Health Professional Division
66. Brook I., and Frazier E.H. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 33 (1995) 2382-2387
67. Gorbach S.L., Bartlett J.G., et al. Infectious diseases. 2nd ed (1998), WB Saunders, Philadelphia
68. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg 87 (2000) 718
69. Stevens D.L. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1 (1995) 69-78
70. Chelsom J., Halstensen A., Haga T., and Hoiby E.A. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 344 (1994) 1111-1115
71. Wong C.H., Chang H.C., Pasupathy S., et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 85-A (2003) 1454-1460
72. Doroghazi R.M., Nadol J.B., et al. Invasive external otitis. Isr J Med 71 (1981) 603
73. Rubin Grandis J., Branstetter IV B.F., and Yu V.L. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis 4 (2004) 34-39
74. Rubin J., and Yu V.L. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med 85 (1988) 391-398
75. Barrow H.N., and Levenson M.J. Necrotizing 'malignant' external otitis caused by Staphylococcus epidermidis. Arch Otolaryngol Head Neck Surg 118 (1992) 94-96
76. Farr R.C., Gardner G., Acker J.D., et al. Blastomycotic cranial osteomyelitis. Am J Otol 13 (1992) 582-586
77. Scherbeuske J.M., Winton G.B., et al. Acute pseudomonas infection of the external ear (malignant external otitis). Dermatol Surg Oncol 14 (1988) 165
78. Munoz A., and Martinez-Chamorro E. Necrotizing external otitis caused by Aspergillus fumigatus: computed tomography and high-resolution magnetic resonance imaging in an AIDS patient. J Laryngol Otol 112 (1998) 98-102
79. Gordon G., and Giddings N.A. Invasive otitis externa due to Aspergillus species: case report and review. Clin Infect Dis 19 (1994) 866-870
80. Bayardelle P., Jolivet-Granger M., and Larochelle D. Staphylococcal malignant external otitis. CMAJ 126 (1982) 155
81. Coser P.L., Stamm A.E., Lobo R.C., and Pinto J.A. Malignant external otitis in infants. Laryngoscope 90 (1980) 312-316
82. Lancaster J., Alderson D.J., and McCormick M. Non-pseudomonal malignant otitis externa and jugular foramen syndrome secondary to cyclosporin-induced hypertrichosis in a diabetic renal transplant patient. J Laryngol Otol 114 (2000) 366-369
83. Scheinfeld N.S. Obesity and dermatology. Clin Dermatol 22 (2004) 303-309
84. Prabhu R.M., and Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 10 Suppl 1 (2004) 31-47
85. Rashid M., Bari A., Majeed S., et al. Mucormycosis: a devastating fungal infection in diabetics. J Coll Phys Surg Pak 15 (2005) 43-45
86. McNulty J.S. Rhinocerebral mucormycosis: predisposing factors. Laryngoscope 92 10 Pt 1 (1982) 1140-1143
87. Sandler R., Tallman C.B., et al. Successfully treated rhinocerebral phycomycosis in well-controlled diabetes. N Engl J Med 285 (1971) 1180
88. De Locht M., Boelaert J.R., and Schneider Y.J. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 47 (1994) 1843-1850
89. Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis 40 (2005) 990-996 [electronic publication 2005 Feb 24]
90. Joachims H.Z., Danino J., and Raz R. Malignant external otitis: treatment with fluoroquinolones. Am J Otolaryngol 9 (1988) 102-105
91. Davis J.C., Gates G.A., Lerner C., et al. Adjuvant hyperbaric oxygen in malignant external otitis. Arch Otolaryngol Head Neck Surg 118 (1992) 89-93
92. Holdiness M.R. Management of cutaneous erythrasma. Drugs 62 (2002) 1131-1141
93. Saltoglu N., Tasova Y., Zorludemir S., and Dundar I.H. Rhinocerebral zygomycosis treated with liposomal amphotericin B and surgery. Mycoses 41 (1998) 45-49
94. Bennett J.E. Goodman and Gilman's The pharmacological basis of therapeutics. 11th ed (2006), McGraw-Hill, New York
95. Richardson T., and Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 4 (2003) 661-667
96. Reeves W., Allen B., and Tattersell R. Insulin induced lipoatrophy: evidence for an immune pathogenesis. BMJ 280 (1980) 1500
97. Young R.J., Hannan W., et al. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 7 (1984) 479
98. Levandoski L.A., White N.H., and Santiago J.V. Localized skin reactions to insulin: insulin lipodystrophies and skin reactions to pumped subcutaneous insulin therapy. Diabetes Care 5 (1982) 6
99. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 18 (1995) 361
100. Thomson MICROMEDEX. All rights reserved. MICROMEDEX(R) Healthcare Series 126; 1974-2005.